Big Picture Bio
AI-powered world model for identifying, designing, and optimizing drug combinations for complex diseases.
Website: https://bigpicturebio.com/
Cover Block
From the public record
| Field | Value |
|---|---|
| Name | Big Picture Bio |
| Tagline | AI-powered world model for identifying, designing, and optimizing drug combinations for complex diseases. |
| Headquarters | London, UK [Crunchbase, retrieved 2026] |
| Founded | 2026 [Crunchbase, retrieved 2026] |
| Stage | Pre-Seed [Crunchbase, retrieved 2026] |
| Business Model | B2B |
| Industry | Deeptech |
| Technology | AI / Machine Learning |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2), Dr Kerstin Papenfuss and Dr Mark Hammond [bigpicturebio.com, September 2026] |
| Funding Label | Pre-seed |
| Total Disclosed Funding | £2.2 million (approximately $3 million) [bigpicturebio.com, September 2026] |
Links
From the public record
- Website: https://bigpicturebio.com/
The Short Version
PUBLIC Big Picture Bio is a London drug-discovery startup building an AI "world model" to identify and optimize combination therapies for complex disease, and it merits attention now because it has emerged from stealth with fresh capital and a thesis that targets one of oncology's harder technical problems, treatment resistance [Big Picture Bio, September 2026] [The Founder Gazette, September 2026]. The company was founded in 2026 by Dr Kerstin Papenfuss and Dr Mark Hammond, both described as former Deep Science Ventures executives, and it surfaced publicly in September 2026 alongside its first disclosed financing [Big Picture Bio, September 2026] [European Biotechnology, September 2026].
The product claim is ambitious but legible: Big Picture Bio says its platform models interactions among tumours, immune cells, and surrounding tissue across disease sites and patient subgroups, with an initial focus on selecting which drugs should be combined and in what sequence before advancing candidates into wet-lab validation [Big Picture Bio, September 2026] [The Founder Gazette, September 2026]. Its stated differentiation rests on a biology-grounded modeling approach, rather than a generic foundation-model layer alone, although the current evidence base is still largely company-led and early external validation claims should be treated cautiously [bigpicturebio.com] [Technology Networks].
On team quality, the relevant signal is domain adjacency rather than prior commercial scale. Papenfuss is identified publicly as co-founder and CEO, Hammond as CTO, and multiple sources link both founders to backgrounds spanning drug discovery, venture creation, and AI-enabled scientific discovery, with advisory ties reported to executives associated with AstraZeneca, Exscientia, and PhoreMost [Anwesha Sarkar - Elsevier | LinkedIn] [Rabab Nasrallah, PhD - Earlybird Venture Capital | LinkedIn] [N24, September 2026].
Funding is modest but coherent for the stage. The company announced £2.2 million in total support in September 2026, comprising a £1.5 million pre-seed round co-led by Kadmos Capital and Exceptional Ventures, with Gloucester Ventures and John White participating, plus £700,000 from the Innovate UK Investor Partnerships Programme; the business model appears B2B, likely oriented to pharma and biotech partners, though no commercial customers have been publicly named [Big Picture Bio, September 2026] [The Founder Gazette, September 2026] [Crunchbase].
Over the next 12 to 18 months, the central question is not whether the narrative is interesting, it is whether the platform can convert computational predictions into reproducible wet-lab results and then into credible partner demand. Investors should watch for named programmes, clearer proof around retrospective and prospective validation, and any evidence that the company can turn its disease-modeling approach into a repeatable discovery engine rather than a one-off scientific demonstration [Big Picture Bio, September 2026] [International Biopharmaceutical Industry] [European Biotechnology, September 2026].
Unconfirmed -- This section relies materially on company press materials and lightly corroborating launch coverage, with several core product and validation claims still company-led or single-source.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Pre-Seed |
| Business Model | B2B |
| Industry / Vertical | Deeptech |
| Technology Type | AI / Machine Learning |
| Geography | Western Europe |
| Growth Profile | Venture Scale |
| Founding Team | Co-Founders (2) |
| Funding | Pre-seed, total disclosed about $3,000,000 [Big Picture Bio, September 2026] |
The Company in Brief
From the public record
Big Picture Bio surfaced publicly in September 2026 with a narrow first claim and a very early balance sheet: it is positioning itself as a London-based drug discovery company using an AI "world model" to design and optimize combination therapies for complex disease [Crunchbase] [Big Picture Bio, September 2026]. The company describes its platform as modeling interactions among tumours, immune cells, and surrounding tissue across disease sites and patient subgroups, with an initial focus on moving computationally designed combinations into wet-lab validation [Big Picture Bio, September 2026].
The chronology is short, which matters for how much weight to place on the launch narrative. Crunchbase lists Big Picture Bio as founded in 2026 and headquartered in London, UK [Crunchbase]. The company website's September 2026 launch materials identify Dr Kerstin Papenfuss as CEO and co-founder and Dr Mark Hammond as CTO and co-founder, and state that the business launched with £2.2 million in combined equity and grant funding [Big Picture Bio, September 2026].
The main public milestone so far is that September 2026 financing event. According to the company, the package included a £1.5 million pre-seed round led by Kadmos Capital and a further £700,000 through the Innovate UK Investor Partnerships Programme, bringing total announced funding to £2.2 million and supporting the transition from in silico design into wet-lab validation [Big Picture Bio, September 2026]. At this stage, the public record supports a launch snapshot more than an operating history, so the company overview is better read as a starting point than as evidence of execution over time.
Unconfirmed -- This section relies materially on company website and company press release disclosures, with only partial corroboration from Crunchbase on founding year and headquarters.
What They Have Built
MIXED
The technical claim worth isolating is straightforward: Big Picture Bio says it is building an AI "world model" to simulate how tumours, immune cells, and surrounding tissue interact across disease sites and patient subgroups, with the first application in combination-therapy design [Big Picture Bio, September 2026] [bigpicturebio.com]. In public descriptions, the product is framed less as a general-purpose biology model and more as a decision system for a narrow but commercially relevant question, namely which drugs should be used together, and potentially in what sequence, to address resistance in cancer and immune-mediated disease [The Founder Gazette, September 2026] [European Biotechnology, September 2026].
The evidence for differentiation remains mostly company-led, so the safer reading is that the novelty sits in the biological representation rather than in any disclosed model architecture [bigpicturebio.com] [Big Picture Bio, September 2026]. Big Picture Bio states that the system is built around human-defined principles governing cancer biology, the immune system, drug resistance, and drug delivery, and that its wedge is AI-assisted discovery followed by wet-lab validation rather than computational prediction alone [N24, September 2026] [Big Picture Bio, September 2026]. Separate public references say the platform has been validated against real-world clinical outcomes presented at ASCO and correctly predicted the failure of Regeneron's fianlimab trial, but neither the underlying benchmark methodology nor the full validation dataset is described in the materials reviewed [Technology Networks] [International Biopharmaceutical Industry].
From an investor standpoint, that leaves a familiar early-stage diligence question: whether the product is best understood as a scientific insight engine, a workflow tool for pharma partners, or the basis for internally generated assets. The public record supports the first of those most clearly today, because the announced use case is identification and optimisation of drug combinations, and the company says its first designed combinations are moving from in silico work into wet-lab validation [Big Picture Bio, September 2026] [The Founder Gazette, September 2026]. What the public materials do not yet establish is the model stack, partner integration layer, or any verified customer deployment, so technical ambition is visible earlier than product proof.
Unconfirmed -- Product scope is corroborated across the company press release and external launch coverage, but most technical and validation claims remain company-led or lightly re-reported.
Market Size and Demand
From the public record
The market matters now because oncology drug development is running into a combination problem that standard single-asset workflows do not solve cleanly, while AI tooling is getting pulled closer to preclinical decision-making even before clear category leaders have emerged [The Founder Gazette, September 2026] [European Biotechnology, September 2026].
Big Picture Bio is pointed at a real bottleneck, but the public record is thin on formal market sizing. No named third-party TAM, SAM, or SOM study for the company’s exact category, AI-driven combination-therapy discovery, appears in the cited materials, so the market has to be framed through analogous public categories rather than direct sizing claims [Big Picture Bio, September 2026] [Crunchbase]. The company’s own positioning is narrower than broad “AI in drug discovery”: it is focused on identifying and optimizing drug combinations, initially in cancer and immune-mediated disease, where treatment resistance and heterogeneous patient response make combination design a recurring scientific and commercial problem [The Founder Gazette, September 2026] [bigpicturebio.com].
Demand drivers in the source set are also fairly specific. The company states that its platform models interactions among tumours, immune cells, and surrounding tissue across disease sites and patient subgroups, with the initial goal of determining which drugs should be used together and potentially in what sequence [Big Picture Bio, September 2026] [The Founder Gazette, September 2026]. That points to a buyer need less about generic model access and more about reducing trial-and-error in preclinical prioritization, especially where resistance mechanisms and microenvironment effects can undermine otherwise promising assets [Big Picture Bio, September 2026] [European Biotechnology, September 2026].
The nearest adjacent markets are computational drug discovery, biomarker-guided oncology development, and translational platforms used to rank in-licensing or partnering opportunities. Substitute approaches include internal pharma biology teams, CRO-led screening, and broader AI drug discovery platforms that start from target identification or de novo molecule design rather than combination optimization [European Biotechnology, September 2026] [Startup Researcher, September 2026]. Big Picture Bio’s public wedge is that it wants to move from in silico predictions into wet-lab validation, which matters because the market will likely reward evidence of experimental translation rather than model sophistication alone [Big Picture Bio, September 2026] [StartupMag, September 2026].
Regulatory and macro forces are present, but only indirectly in the public evidence. The inclusion of Innovate UK Investor Partnerships Programme funding suggests a policy environment in the UK that is still willing to support early deeptech and biotech infrastructure bets, particularly those that combine scientific computing with translational ambition [Big Picture Bio, September 2026]. At the same time, the absence of disclosed customers, named programs in clinic, or published commercial partnerships means the market signal today is investor and grant appetite, not proven procurement demand from pharma buyers [Crunchbase] [The Founder Gazette, September 2026].
| Market lens | Publicly supported observation | Relevance to Big Picture Bio |
|---|---|---|
| Analogous category: AI in drug discovery | Coverage places the company within AI-enabled drug discovery rather than a standalone established software category [European Biotechnology, September 2026] [Startup Researcher, September 2026] | Useful for framing investor attention, but too broad to stand in for direct TAM |
| Sub-segment: combination-therapy discovery | Big Picture Bio’s stated initial goal is to identify and optimize combination therapies and sequencing [The Founder Gazette, September 2026] [Big Picture Bio, September 2026] | This appears to be the practical entry market |
| Initial disease wedge | Initial focus is cancer and immune-mediated disease [The Founder Gazette, September 2026] | Suggests a higher-value but scientifically demanding starting point |
| Commercial translation path | The company says funding will help move first designed combinations into wet-lab validation [Big Picture Bio, September 2026] | Implies value capture depends on proof generation, not software distribution alone |
The table shows the main limitation in the public market case: the problem area is legible, but the size of the addressable budget is not yet quantified from independent market research. For investors, that shifts attention from category size claims to whether the company can earn a place in pharma R&D workflows through validated combination-ranking performance.
Unconfirmed -- This section relies primarily on company materials and launch coverage to frame an analogous market, with no independent third-party TAM, SAM, or SOM report identified in the cited sources.
Who Else Is Fighting for This
Landscape
MIXED Big Picture Bio is positioning itself in the crowded computational-biology stack not as a general-purpose AI drug-discovery platform, but as a narrower bet on combination-therapy design where resistance biology, sequencing, and tumour microenvironment effects matter more than single-asset screening [Big Picture Bio, September 2026] [The Founder Gazette, September 2026].
That distinction matters because the nearest alternatives are not clearly disclosed by the company or the coverage around its launch, and the public record does not yet name direct competitors in its materials [Big Picture Bio, September 2026] [European Biotechnology, September 2026]. In practice, the company appears to sit at the intersection of three groups: established AI drug-discovery platforms with broader scope, oncology specialists working on treatment response and resistance, and traditional wet-lab combination discovery programs inside pharma and biotech that do not rely on a generative "world model" framing [bigpicturebio.com, retrieved 2026] [The Founder Gazette, September 2026]. The first group has more resources and often more mature business-development machinery; the third group has disease-program ownership and experimental control, but can be slower and less scalable when searching large combination spaces.
The edge visible in public sources is narrower than the launch language suggests, but it is not trivial. Big Picture Bio says its system models interactions among tumours, immune cells, and surrounding tissue across disease sites and patient subgroups, and multiple write-ups describe the company as founded by former Deep Science Ventures executives with backgrounds spanning drug discovery, venture creation, and AI-enabled scientific discovery [Big Picture Bio, September 2026] [European Biotechnology, September 2026] [linkedin.com, retrieved 2026]. If that team can translate biological priors into a usable model architecture, the early advantage is likely talent density and problem selection rather than distribution. That edge is also perishable. Founding-team credibility can open doors for pilot work, but it does not by itself create a durable moat unless the company compounds proprietary validation data or secures repeat pharma workflows that improve the model over time.
The main exposure is straightforward. Big Picture Bio has announced funding, technical ambition, and a wet-lab validation plan, but the public evidence does not yet identify named customers, commercial programs, or recurring partnerships tied specifically to this platform's output [Big Picture Bio, September 2026] [Crunchbase, retrieved 2026]. That leaves the company vulnerable to broader AI-drug-discovery firms that already have pharma channel access and to internal translational-oncology teams that can test combinations against proprietary assays without buying an external platform. It is also exposed to proof burden. Claims such as validation against real-world clinical outcomes and correctly predicting the failure of Regeneron's fianlimab trial are directionally interesting, but the cited public sources do not provide enough technical detail to judge how repeatable that performance is across programs [Technology Networks] [International Biopharmaceutical Industry].
The most plausible 18-month scenario is that competition is decided less by algorithm branding and more by who turns predictions into partner-grade evidence. Big Picture Bio is the likely winner if its first wet-lab results show that the model can surface combinations or sequencing insights that standard screening workflows would have missed, particularly in oncology settings where resistance is the gating problem [Big Picture Bio, September 2026] [The Founder Gazette, September 2026]. Big Picture Bio is also the likely loser if wet-lab validation proves slower than expected or if the model's outputs are hard for pharma partners to interpret and operationalize, because larger AI discovery platforms and incumbent drug developers can absorb iteration cycles more easily. For now, the company's competitive posture reads as technically differentiated but commercially pre-proof.
Unconfirmed -- This section relies mainly on company materials and launch coverage, with no publicly confirmed named competitors and limited independent validation of comparative performance.
Opportunity
Upside case
PUBLIC The prize here is unusually large because combination-therapy discovery sits close to one of pharma's most expensive bottlenecks: picking the right drugs, in the right sequence, for biologically messy diseases where single-agent approaches often run into resistance [The Founder Gazette, September 2026] [bigpicturebio.com, September 2026]. If Big Picture Bio can show that its world-model approach improves hit quality early enough for partners to change portfolio decisions, it has a path to becoming a repeat discovery engine for combination programs rather than a one-asset biotech [European Biotechnology, September 2026] [bigpicturebio.com, September 2026].
The headline opportunity is not simply to recommend interesting pairings. It is to become a software-and-science layer that pharma and biotech teams use when they need to decide which combinations deserve capital, lab time, and clinical sequencing work across cancer and immune-mediated disease [The Founder Gazette, September 2026] [Sebastian A. Brunemeier - Healthspan Capital | LinkedIn]. That outcome is still early and mostly company-described, but it is not detached from the evidence: the company launched with dedicated pre-seed capital, non-dilutive support from Innovate UK, and a stated plan to move from in silico design into wet-lab validation, which is the right bridge if it wants to convert computational claims into partner-grade evidence [bigpicturebio.com, September 2026] [Crunchbase].
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Discovery engine for combination oncology | Big Picture Bio signs recurring collaborations with pharma and biotech partners that use the platform to prioritize combination candidates in resistant cancers | A first externally validated wet-lab result or partnership tied to combination selection | The company is explicitly focused on identifying and optimizing combination therapies for cancer, and says its first designed combinations are moving toward wet-lab validation [The Founder Gazette, September 2026] [bigpicturebio.com, September 2026] |
| Default platform for complex-disease combinations | The initial oncology wedge expands into immune-mediated disease, giving the company a broader platform position across diseases where cell, tissue, and treatment interactions are hard to model | Proof that the same modeling framework transfers beyond oncology | The company's public materials frame the platform around interactions among tumours, immune cells, and surrounding tissue, and cite cancer plus immune-mediated disease as the first focus areas [bigpicturebio.com, September 2026] [The Founder Gazette, September 2026] |
| From recommender to designer | The business moves from optimizing existing drug combinations toward helping design new treatments, increasing strategic value and economics per program | Strong enough biological and validation evidence that partners trust the system for earlier-stage invention work | Management has already described the longer-term ambition as designing new treatments rather than only recombining existing medicines [The Founder Gazette, September 2026] |
The compounding mechanism, if it appears, is straightforward. Each validated prediction should improve credibility with partners, each partner program should create more edge cases around resistance and sequencing, and each additional dataset should sharpen where the model's human-defined biological rules help more than generic foundation approaches [bigpicturebio.com, retrieved 2026] [europesays.com]. The company has also pointed to validation against real-world clinical outcomes and to a claimed call on a recent Regeneron trial failure, both of which matter because this category is won less by elegant modeling claims than by repeated evidence that the system changes go or no-go decisions in the right direction [Technology Networks] [International Biopharmaceutical Industry].
The size of the win is best framed as strategic platform value rather than near-term revenue arithmetic. Public market or M&A comparables for this exact company are not established in the source set, and no market-sizing figure is confirmed here, so the cleaner way to state the upside is conditional: if Big Picture Bio becomes a trusted discovery partner for multiple oncology and immunology programs, it could resemble the kind of platform biotechs or AI-enabled drug discovery companies that command outsized value because they sit upstream of many shots on goal (scenario, not a forecast) [European Biotechnology, September 2026] [Startup Researcher, September 2026]. What makes that scenario worth taking seriously, despite the early stage, is that the company is aiming at a real cost center in R&D and has chosen a wedge, combination selection plus wet-lab follow-through, that can produce discrete proof points before any clinical asset is fully built [bigpicturebio.com, September 2026] [The Founder Gazette, September 2026].
Unconfirmed -- This section relies materially on company statements and launch coverage, with limited independent public corroboration beyond funding and founder background [bigpicturebio.com, September 2026] [Crunchbase].
Sources
From the public record
[Crunchbase, retrieved 2026] Big Picture Bio | Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/big-picture-bio
[bigpicturebio.com, September 2026] Press Release 17 September 2026 | https://bigpicturebio.com/press/big-picture-bio-launch-17-september-2026.pdf
[The Founder Gazette, September 2026] Big Picture Bio leaves stealth with £2.2m, £700k of it non-dilutive | https://www.thefoundergazette.com/stories/big-picture-bio-leaves-stealth-with-2-2m-700k-of-it-non-dilu
[European Biotechnology, September 2026] Big Picture Bio launches with £2.2M to design cancer combinations | https://european-biotechnology.com/latest-news/big-picture-bio-launches-with-2-2m-to-design-cancer-combinations/
[bigpicturebio.com] Big Picture Bio | The world model for combination therapy | https://bigpicturebio.com/
[Anwesha Sarkar - Elsevier | LinkedIn, retrieved 2026] Anwesha Sarkar | LinkedIn | https://www.linkedin.com/in/anweshasarkar/
[Rabab Nasrallah, PhD - Earlybird Venture Capital | LinkedIn, retrieved 2026] Rabab Nasrallah, PhD | LinkedIn | https://www.linkedin.com/in/rabab-nasrallah-phd-04918593/
[N24, September 2026] Big Picture Bio Secures €2.55M for AI Cancer Therapy | https://n24.com.tr/en/health/big-picture-bio-secures-255m-for-ai-cancer-therapy-791
[Technology Networks, retrieved 2026] Big Picture Bio | Technology Networks | https://www.technologynetworks.com/
[International Biopharmaceutical Industry, retrieved 2026] International Biopharmaceutical Industry | https://international-biopharma.com/
[Startup Researcher, September 2026] Big Picture Bio Emerges From Stealth With €2.55 Million | https://www.startupresearcher.com/news/big-picture-bio-emerges-from-stealth-with-eur2-55-million
[StartupMag, September 2026] Big Picture Bio raises £1.5m from Kadmos and Exceptional | https://www.startupmag.co.uk/funding/big-picture-bio-2026-seed-funding/
[Sebastian A. Brunemeier - Healthspan Capital | LinkedIn, retrieved 2026] Sebastian A. Brunemeier | LinkedIn | https://www.linkedin.com/in/sebastianlongbio/
[europesays.com] Big Picture Bio | europesays.com | https://europesays.com/
Articles about Big Picture Bio
- Kadmos Capital Leads a Pre-Seed for AI-Driven Combination Therapy — The London startup, founded by Deep Science Ventures alumni, is using its initial funding to move AI-designed drug combinations into wet-lab validation.